Amsbio expands CAR-T research tools with sterile cell line portfolio
Amsbio has launched an expanded portfolio of ready-to-use, sterile cell lines designed to accelerate CAR-T cell therapy research for leukaemia treatment. The offering addresses growing demand for standardised cellular tools following the 2017 FDA approval of CAR-T therapy for children and adolescents with B cell acute lymphoblastic leukaemia (ALL).
Targeting multiple antigens to overcome treatment resistance
The initial FDA-approved CAR-T therapies targeted CD19, a B cell surface protein. Building on this foundation, researchers have demonstrated that multi-antigen targeting strategies offer measurable advantages in clinical outcomes.
“This success inspired new research that demonstrated CAR-T cell therapy targeting multiple B cell proteins offers improved cancer treatment by reducing tumour recurrence from antigen escape, enhancing anti-tumour efficacy through synergistic recognition, overcoming tumour heterogeneity, and potentially improving treatment specificity,” said Dr Maja Petkovic, Business Development Manager at Amsbio.
Comprehensive cellular toolkit for immunotherapy research
The company’s cell line catalogue includes knockout variants for TCR, B2M, and CIITA genes, enabling researchers to model universal CAR-T cells that may evade immune rejection. Additionally, Amsbio provides sterile, pathogen- and mycoplasma-free cell lines expressing common CAR targets including BCMA, CD19, CD20, and CD22. Many lines incorporate luciferase reporters for simplified monitoring in experimental systems.
“Amsbio now can also offer ready-to-use CAR-expressing cells for assay design/optimisation and as positive controls in co-culture assays, as well as bispecific CAR T cells targeting CD19 & CD22,” Dr Petkovic added.
Supporting translational research infrastructure
The portfolio forms part of Amsbio’s broader life science technology platform, which encompasses extracellular matrix expertise, 3D culture systems including organ-on-a-chip microfluidics, and a comprehensive biorepository of human and animal tissue specimens. The company also maintains clinicalgrade products for stem cell and cell therapy applications, including GMP cryopreservation technology. These standardised research tools aim to reduce experimental variability and accelerate the pathway from laboratory discovery to clinical application in cellular immunotherapy.
For more information, visit: https://www.amsbio.com/car-t-cell-research
Digital issue: Please click here for more information
